98%
921
2 minutes
20
The DIO2 Thr92Ala polymorphism (rs225014), which occurs in about 15-30% of Caucasian people, determines a less efficient type 2 deiodinase (D2) enzyme. The aim of this study was to determine the impact of DIO2 Thr92Ala polymorphism on the serum thyrotropin (TSH) levels in thyroidectomized patients with hypothyroidism and to evaluate whether TSH levels and aging could be related, at pituitary level, to D2 activity. This prospective study was performed on 145 thyroid cancer patients, treated with total thyroidectomy, and undergoing radioiodine treatment after 3 weeks of levothyroxine (LT4) withdrawal. A mouse model has been used to determine D2 protein and mRNA levels in pituitary during aging. Genetic analysis identified DIO2 Thr92Ala polymorphism in 56% of participants: 64/145 (44%) patients were homozygous wild type (WT) (Thr/Thr), 64 (44%) heterozygous (Thr/Ala), and 17 (12%) homozygous mutant (Ala/Ala). A significant negative relationship was observed between aging and the rise in serum TSH levels during LT4 withdrawal. However, this negative correlation found in WT was reduced in heterozygous and lost in mutant homozygous patients (Thr/Thr = -0.45, = 0.0002, 95% confidence interval [CI] -0.63 to -0.23; Ala/Thr = -0.39, = 0.0012, CI -0.60 to -0.67; and Ala/Ala = -0.30, = 0.2347; CI -0.70 to 0.20). Accordingly, when we compared the TSH measured in each patient to its theoretical value predicted from age, the TSH did not reach its putative target in 47% of WT patients, in 70% of Ala/Thr, and 76% of Ala/Ala carrying patients ( = 0.0036). This difference was lost in individuals older than 60 years, suggesting a decline of D2 associated with aging. The hypothesis that the pituitary D2 decreases with age was confirmed by the evidence that D2 mRNA and protein levels were lower in pituitary from old versus young mice. An age-related decline in TSH production in response to hypothyroidism was correlated with decreased D2 levels in pituitary. The presence of 2 homozygous Ala/Ala polymorphism was associated with a reduced level of TSH secretion in response to hypothyroidism, indicating a decreased pituitary sensitivity to serum thyroxine variation (Institutional Research Ethics board approval number no. 433/21).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/thy.2022.0472 | DOI Listing |
Cureus
August 2025
Endocrinology, Metabolic Center for Wellness, Oviedo, USA.
Levothyroxine (T4) monotherapy remains the standard of care for hypothyroidism worldwide. However, a subset of patients continues to report persistent symptoms, such as fatigue, depression, and cognitive difficulties, despite normalized thyroid-stimulating hormone (TSH) levels. This has reignited clinical interest in the active thyroid hormone triiodothyronine (T3) and combination T4/T3 therapies.
View Article and Find Full Text PDFJ Cell Mol Med
July 2025
Department of Immunology, Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye.
Thyroid hormone modulates multiple neurotransmitter systems, including dopaminergic, serotonergic, glutamatergic and GABAergic pathways, which are implicated in schizophrenia (SCH) pathophysiology. The Type II deiodinase (DIO2) enzyme plays a critical role in thyroid metabolism, converting thyroxine (T4) into the biologically active triiodothyronine (T3). This study aimed to investigate the potential association between DIO2 gene polymorphisms, Thr92Ala and ORFa-Gly3Asp, with serum levels of free triiodothyronine (fT3), free thyroxine (fT4) and thyroid-stimulating hormone (TSH) in SCH susceptibility and symptomatology.
View Article and Find Full Text PDFEndocrinology
March 2025
Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555, USA.
The Thr92Ala-Dio2 polymorphism is prevalent worldwide, with about 50% of the population carrying at least 1 allele. The Ala92-Dio2 allele encodes a less active type 2 deiodinase enzyme and has been associated with neurodegenerative diseases, hypertension, and insulin resistance. To understand why its phenotypic effects are variable across different populations, in this study we examined the impact of genetic background on the Thr92Ala-Dio2 polymorphism.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
June 2024
Post-Graduate Program in Medicine and Health, Medical School of Medicine, Federal University of Bahia, Salvador, Brazil.
Eur Thyroid J
August 2024
Post-Graduate Program in Medicine and Health, Medical School of Medicine, Federal University of Bahia, Salvador, Brazil.
Introduction: The type 2 deiodinase and its Thr92Ala-DIO2 polymorphism have been linked to clinical outcomes in acute lung injury and coronavirus disease 2019 (COVID-19).
Objective: The objective was to identify a potential association between Thr92Ala-DIO2 polymorphism and body composition (appendicular muscle mass, myosteatosis, and fat distribution) and to determine whether they reflect the severity or mortality associated with the disease.
Methods: In this prospective cohort study (June-August 2020), 181 patients hospitalized with moderate-to-severe COVID-19 underwent a non-contrast-enhanced computed tomography (CT) of the thorax to assess body composition, laboratory tests, and genotyping for the Thr92Ala-DIO2 polymorphism.